Cepheid's BCR-ABL Ultra

Cepheid has begun shipping the CE-IVD marked Xpert BCR-ABL Ultra test to quantitate mRNA transcripts in patients with chronic myelogenous leukemia undergoing tyrosine kinase inhibitor treatment. The assay is an updated version of the Xpert BCR-ABL Monitor test that provides increased sensitivity, the firm said. It is aligned to the International Scale on a lot-to-lot basis, increasing reliability of comparisons between labs, and uses the Cepheid GeneXpert system to deliver results in less than two and a half hours.